Skip to main content
. 2017 Aug 9;6(1):18–23. doi: 10.1016/j.prnil.2017.07.001

Fig. 3.

Fig. 3

PFS and OS in patients with castration-resistant prostate cancer treated with first- or second-line AA. (A) PFS in patients treated with first-line AA or second-line AA after flutamide. (B) OS in patients treated with first-line AA or second-line AA after flutamide. AA, abiraterone acetate; n.s., not significant; OS, overall survival; PFS, progression-free survival.